Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Melanoma 1Lymphopenia 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

Irinotecan 30Paclitaxel 24Gemcitabine 21Cisplatin 21Docetaxel 19Fluorouracil 15alvocidib 12Oxaliplatin 11Leucovorin 11Carboplatin 11Capecitabine 11Bortezomib 9Taxes 8Topotecan 73-aminopyridine-2-carboxaldehyde thiosemicarbazone 7Vorinostat 6Immunohistochemistry 6tanespimycin 5Temozolomide 5Sorafenib 5Pemetrexed 5Early Intervention, Educational 5Chromatography, High Pressure Liquid 5Bevacizumab 57-hydroxystaurosporine 57-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine 5ixabepilone 4bryostatin 1 4Sirolimus 4Pharmacogenomic Testing 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Unspecified Adult Solid Tumor, Protocol Specific × Interleukin-7 × Clear all
NCT00062049 2012-03-08

Interleukin-7 in Treating Patients With Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
30 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡